-
US buys additional 650,000 doses of Lilly’s Covid-19 antibody for $812.5m
pharmaceutical-technology
December 04, 2020
The US government has entered into a purchase agreement worth $812.5m to procure 650,000 additional doses of Eli Lilly and Company’s neutralising antibody bamlanivimab (LY-CoV555) 700mg.
-
BioInvent signs monoclonal antibody manufacturing deal with Cantargia
pharmaceutical-technology
November 30, 2020
Clinical stage firm BioInvent International and Cantargia have signed a manufacturing agreement for monoclonal antibody CAN10 to treat systemic sclerosis and myocarditis.
-
Lilly, Samsung Partner to Mass Produce COVID-19 Antibody
americanpharmaceuticalreview
November 25, 2020
Samsung Biologics' partnership with Eli Lilly and Company is expected to accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the goal of making antibody treatments more globally ...
-
Regeneron's COVID-19 Antibody Cocktail Gets EUA
contractpharma
November 24, 2020
Expects to have treatment doses ready for approximately 80,000 patients by the end of November, and 200,000 by the first week of January.
-
Samsung Biologics Partners with Eli Lilly
contractpharma
November 23, 2020
Samsung Biologics has entered a strategic manufacturing partnership with Eli Lilly to accelerate the global supply for Lilly’s Covid-19 antibody therapies with the ultimate goal of making antibody treatments more globally accessible for patients.
-
AstraZeneca begins trials on antibody cocktail to prevent COVID-19
expresspharma
November 23, 2020
The prophylactic treatment may prove useful in people whose immune systems are weaker or compromised, and who don’t respond to vaccination.
-
Chinese vaccine candidate based on inactivated SARS-CoV-2 virus appears safe and induces an immune response in healthy volunteers
worldpharmanews
November 20, 2020
Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lancet Infectious Diseases journal, finding the formulation appears safe and induces ...
-
Cipla signs licensing pact with MultiG for COVID-19 rapid antibody test kit
expresspharma
November 19, 2020
'Covi-G' has been commercialised in 20+ countries, with sensitivity and specificity exceeding 92 per cent, informs company.
-
FDA grants emergency use authorisation to COVID-19 antibody bamlanivimab
europeanpharmaceuticalreview
November 13, 2020
The neutralising antibody therapy bamlanivimab (LY-CoV555) is authorised for emergency use in recently diagnosed patients who are at risk of developing severe COVID-19.
-
Llama nanobodies could be a powerful weapon against COVID-19
worldpharmanews
November 10, 2020
The researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to ...